These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 19231913

  • 1. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [Abstract] [Full Text] [Related]

  • 2. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, Heidari H, SeyedAlinaghi S, Voltarelli F.
    Recent Pat Antiinfect Drug Discov; 2018 Apr; 13(3):228-239. PubMed ID: 30360748
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
    Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, Reichl V, Freitag S, Bahal N, Wiesinger BA, Tennenberg A, Kahn JB.
    Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
    [Abstract] [Full Text] [Related]

  • 4. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM.
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [Abstract] [Full Text] [Related]

  • 5. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP, Matchar DB, Harnett J, Wilson J.
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.
    Treat Respir Med; 2004 Nov; 3(5):329-36. PubMed ID: 15606222
    [Abstract] [Full Text] [Related]

  • 8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 9. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC, Davis CW.
    Am J Health Syst Pharm; 2000 Nov 15; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [Abstract] [Full Text] [Related]

  • 10. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
    Suzuki J, Sasabuchi Y, Hatakeyama S, Matsui H, Sasahara T, Morisawa Y, Yamada T, Yasunaga H.
    J Infect Chemother; 2019 Dec 15; 25(12):1012-1018. PubMed ID: 31227381
    [Abstract] [Full Text] [Related]

  • 11. A clinical pathway for community-acquired pneumonia: an observational cohort study.
    Frei CR, Bell AM, Traugott KA, Jaso TC, Daniels KR, Mortensen EM, Restrepo MI, Oramasionwu CU, Ruiz AD, Mylchreest WR, Sikirica V, Raut MR, Fisher A, Schein JR.
    BMC Infect Dis; 2011 Jul 06; 11():188. PubMed ID: 21733161
    [Abstract] [Full Text] [Related]

  • 12. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project.
    Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT.
    Pharmacotherapy; 2003 Sep 06; 23(9):1167-74. PubMed ID: 14524648
    [Abstract] [Full Text] [Related]

  • 13. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M, Todisco T, Feldman C, Garbino J, Blasi F, Hogan P, de Caprariis PJ, Hoepelman IM.
    Clin Microbiol Infect; 2007 Feb 06; 13(2):162-171. PubMed ID: 17328728
    [Abstract] [Full Text] [Related]

  • 14. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, Ruiz JL, Burgess DS.
    Clin Ther; 2010 Feb 06; 32(2):293-9. PubMed ID: 20206787
    [Abstract] [Full Text] [Related]

  • 15. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB, American Thoracic Society.
    Arch Intern Med; 2003 Jul 28; 163(14):1718-26. PubMed ID: 12885688
    [Abstract] [Full Text] [Related]

  • 16. Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.
    Berger A, Edelsberg J, Oster G, Huang X, Weber DJ.
    Am J Med Sci; 2014 May 28; 347(5):347-56. PubMed ID: 24029796
    [Abstract] [Full Text] [Related]

  • 17. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S.
    Curr Med Res Opin; 2005 Feb 28; 21(2):261-70. PubMed ID: 15801997
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR, Lemonovich TL.
    Am Fam Physician; 2011 Jun 01; 83(11):1299-306. PubMed ID: 21661712
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus.
    So W, Crandon JL, Nicolau DP.
    Intern Emerg Med; 2016 Jun 01; 11(4):545-51. PubMed ID: 26531307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.